Astromech Raises $20M at $3.8B Valuation
Astromech raises $20M in funding at a $3.8B valuation to scale its AI-driven predictive biology platform for genomic research and cellular longevity.
Astromech Raises $20M at $3.8B Valuation
Astromech, a Dallas, Texas-based computational biology and predictive artificial intelligence startup, has raised $20 million in new funding, bringing its total capital raised to $60 million at a valuation of $3.8 billion.
Investors
The funding round was led by Bob Nelsen, co-founder of ARCH Venture Partners, with participation from NeoGenesis Capital, Builders VC, and a syndicate of genomics-focused venture funds.
Astromech Use of Funds
The company will use the capital to expand its specialized machine learning and computational biology research teams, acquire new multi-species genomic datasets, and build out the heavy computing infrastructure required to scale its foundational AI models.
About Astromech
Founded as a spin-out from Colossal Biosciences, Astromech develops advanced AI-driven predictive world models for biology. The platform analyzes historical genomic datasets to forecast biological outcomes, with an initial focus on cellular longevity and defense mechanisms against cellular aging.
Funding Details
Company Website: https://astromech.com
Company: Astromech
Raised: $20M
Funding Date: August 21, 2026
Lead Investor: Bob Nelsen
Additional Investors: NeoGenesis Capital, Builders VC, syndicate of genomics-focused venture funds
Software Category: Artificial Intelligence / Computational Biology
